Better diagnosis, treatment, and drug-resistance testing for HIV-2
Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection
New approaches to diagnose and treat people with HIV-2 and to spot drug resistance quickly.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11183082 on NIH RePORTER |
What this research studies
This project aims to make diagnosis and treatment simpler for people living with HIV-2, especially in West and Central Africa where HIV-2 is more common. Researchers are working on easy clinic-based viral load tests and methods to detect drug resistance in real time when medicines stop working. They will also look at how the commonly used single-tablet regimen tenofovir-lamivudine-dolutegravir works for HIV-2 and for people with both HIV-1 and HIV-2. The goal is to help clinics choose the right drugs faster so people stay on effective treatment.
Who could benefit from this research
Good fit: People living with HIV-2 or with HIV-1/HIV-2 dual infection, particularly those starting or having trouble with dolutegravir-based first-line therapy, would be the ideal candidates.
Not a fit: People without HIV or those with only HIV-1 in well-resourced settings with established testing and treatment may not see direct benefit from this work.
Why it matters
Potential benefit: Could lead to faster, cheaper diagnosis and earlier detection of drug resistance so people with HIV-2 can stay on effective medicines.
How similar studies have performed: Dolutegravir-based regimens and viral-load testing have greatly helped HIV-1 care, but long-term effectiveness and rapid resistance testing specifically for HIV-2 remain less proven.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Gottlieb, Geoffrey Scott — University of Washington
- Study coordinator: Gottlieb, Geoffrey Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.